Metagenics Names Patrick Sly as CEO to Lead Next Chapter of Growth

Metagenics, announced it has named Patrick Sly as CEO, effective immediately. A highly regarded executive in the health and wellness industry, Mr. Sly brings a wealth of relevant leadership experience to Metagenics. Current President and CEO Pat Smallcombe, who has led Metagenics through a period of tremendous growth since 2023, will transition to the role of Co-Chair of the Board. Metagenics is backed by Gryphon Investors, a leading middle-market private investment firm.

Ryan Fagan, Deal Partner in Gryphon's Consumer Group, said, "With Patrick's deep experience in medical nutrition, partnerships with healthcare professionals, and leadership of global businesses, I couldn't imagine a stronger candidate to succeed Pat Smallcombe's successful tenure. Patrick's leadership style focuses on integrity, innovation, and collaboration, an ideal fit for Metagenics' culture."

"I'm thrilled to be joining Metagenics at such an exciting time," said Mr. Sly. "The professional segment of the supplements category has tremendous growth potential, and Metagenics' outstanding brand and clinically tested product line position the company for continued success. I'm especially impressed by the very strong team and solid foundation that Pat Smallcombe has built, and I look forward to working with the organization to drive the next phase of growth."